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Abstract
Background:  Chlorogenic acid (CHL), the most potent functional inhibitor of the microsomal glucose-6-
phosphate translocase (G6PT), is thought to possess cancer chemopreventive properties. It is not known,
however, whether any G6PT functions are involved in tumorigenesis. We investigated the effects of CHL and the
potential role of G6PT in regulating the invasive phenotype of brain tumor-derived glioma cells.
Results: RT-PCR was used to show that, among the adult and pediatric brain tumor-derived cells tested, U-87
glioma cells expressed the highest levels of G6PT mRNA. U-87 cells lacked the microsomal catalytic subunit
glucose-6-phosphatase (G6Pase)-α but expressed G6Pase-β which, when coupled to G6PT, allows G6P hydrolysis
into glucose to occur in non-glyconeogenic tissues such as brain. CHL inhibited U-87 cell migration and matrix
metalloproteinase (MMP)-2 secretion, two prerequisites for tumor cell invasion. Moreover, CHL also inhibited
cell migration induced by sphingosine-1-phosphate (S1P), a potent mitogen for glioblastoma multiform cells, as
well as the rapid, S1P-induced extracellular signal-regulated protein kinase phosphorylation potentially mediated
through intracellular calcium mobilization, suggesting that G6PT may also perform crucial functions in regulating
intracellular signalling. Overexpression of the recombinant G6PT protein induced U-87 glioma cell migration that
was, in turn, antagonized by CHL. MMP-2 secretion was also inhibited by the adenosine triphosphate (ATP)-
depleting agents 2-deoxyglucose and 5-thioglucose, a mechanism that may inhibit ATP-mediated calcium
sequestration by G6PT.
Conclusion: We illustrate a new G6PT function in glioma cells that could regulate the intracellular signalling and
invasive phenotype of brain tumor cells, and that can be targeted by the anticancer properties of CHL.
Background
The beneficial effects of dietary polyphenols on human
health have been widely assumed to act through various
biological effects such as free radical scavenging, metal
chelation, modulation of enzymatic activity and altering
signal transduction pathways [1-3]. Epidemiological stud-
ies have also highlighted the association between the con-
sumption of polyphenol-rich food and beverages and the
prevention of various human diseases [4,5]. Among these
polyphenols, the antitumor activities of flavonoids as well
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as the inhibition of carcinogenesis by polyphenols has
revealed properties beneficial for the use of nutraceuticals
in cancer therapy [6-8]. Among the sources of these anti-
cancer polyphenols, modern phytochemical research
shows that tea contains a large number of plant secondary
metabolites exhibiting different chemical structures such
as amino acids, catechins, purine alkaloids, and chloro-
genic acid (CHL), and where each group of compounds
possesses some unique biological properties [9]. While
green tea catechins have now been established as having
chemopreventive effects [10,11], the impact of CHL, to
which have been attributed possible cancer chemopreven-
tion properties, is not well understood [12,13]. Interest-
ingly, CHL inhibition of matrix metalloproteinase
(MMP)-9 secretion, an MMP known to be involved in
tumor cell invasion and metastasis, was recently reported
but the anti-cancer intracellular molecular mechanisms
through which CHL effects occur are remained unex-
plored [14]. This property, however, adds up to CHL's
antioxydant and anti-inflammatory properties [15,16].
CHL derivatives have been shown to selectively inhibit
endoplasmic reticulum (ER) glucose-6-phosphate (G6P)
transport, and hence microsomal glucose-6-phosphatase
(G6Pase) activity both in isolated microsomes [17] and in
vivo  [18,19]. CHL is a specific, reversible, competitive
inhibitor of G6PT [20], and it has no effect on the intralu-
minal, G6P-hydrolytic subunit [21]. In intact cells, the
CHL derivative and G6PT inhibitor S3483 was found to
inhibit G6P transport in microsomes isolated from poly-
morphonuclear neutrophils (PMN) and from differenti-
ated promyelocytic HL-60 cells [22]. Interestingly, the
PMN phenotype in glycogen storage disease (GSD) type
1b, a clinical condition where the G6PT gene or protein is
defective [22,23], includes diminution in several proc-
esses such as respiratory burst, chemotaxis, phagocytosis
and calcium signalling [24-26]. Alterations in several bio-
chemical parameters – glucose phosphorylation, calcium
mobilization, and hexose uptake and transport – have
been described as possible mechanisms through which
the G6PT functional defects may be involved [27-29].
Since cells such as PMN have no detectable G6Pase activ-
ity, G6PT must play a role different from that exerted in
the liver, for instance, where it is functionally coupled to
the G6Pase enzyme. Moreover, G6PT functions have
never been investigated in brain tumor-derived cells. It
has been hypothesized that G6PT might function as a G6P
receptor/sensor [23] or that it could favor calcium seques-
tration in the ER lumen [30]. Such roles have not yet been
evidenced, neither the alternate potential G6PT-regulated
cellular functions explored.
In the present work two topics have been addressed. Does
functional inhibition of G6PT regulate any brain tumor-
derived cells' tumorigenic properties, such as MMP-medi-
ated extracellular matrix (ECM) hydrolytic activity or cell
migration ? If so, can a connection be made between
G6PT functions and a role in intracellular signalling that
regulates the invasive phenotype ? Inhibition of the
microsomal G6PT functions was modeled by the addition
of CHL, which is a highly specific inhibitor of G6PT [31],
while upregulation of G6PT was performed through
cDNA transient transfection. The results demonstrate that
G6PT may regulate the brain tumor-derived invasive phe-
notype by controlling intracellular signalling that leads to
cell migration. Moreover, we provide the first molecular
rationale for the anticancer properties of CHL in the regu-
lation of MMP secretion.
Results
U-87 glioma cells express the highest levels of G6PT 
transcript among brain tumor-derived cell lines
Gene expression levels of the microsomal glucose-6-phos-
phate transporter (G6PT), as well as of the two glucose-6-
phosphatase α and β isoforms, were first assessed. Total
RNA was extracted from HEP-G2 hepatoma and U-87 gli-
oma cells, and then RT-PCR was performed as described
in the Methods section. As expected for a cell line derived
from a neoglucogenic tissue, we show that HEP-G2 cells
U-87 glioma cells express G6PT and G6Pase-β transcripts  with the highest G6PT transcript levels among brain tumor- derived cell lines Figure 1
U-87 glioma cells express G6PT and G6Pase-β tran-
scripts with the highest G6PT transcript levels 
among brain tumor-derived cell lines. Several brain 
tumor-derived cell lines (glioma : U-87, U-118, U-138; 
medulloblastoma : DAOY) were cultured until cells reached 
approximately 90% confluence. Total RNA was extracted 
and RT-PCR performed in order to generate the cDNA that 
reflects the gene expression levels of G6PT (380 bp), 
G6Pase-α (360 bp), and G6Pase-β (236 bp) as described in 
the methods section. HEP-G2 hepatoma cells were used as 
positive controls for the presence of all three genes. GAPDH 
gene expression was used as an internal control for each cell 
line tested.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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The G6PT inhibitor chlorogenic acid reduces proMMP-2 secretion in U-87 glioma cells Figure 2
The G6PT inhibitor chlorogenic acid reduces proMMP-2 secretion in U-87 glioma cells. (A) U-87 glioma cells were 
serum-starved in the presence of increasing concentrations of CHL and of the green tea catechin EGCg for 18 hrs. Condi-
tioned media was collected and proMMP-2 gelatinolytic activity assessed by zymography as described in the methods section. 
(B) The extent of proMMP-2 hydrolytic activity was quantified by scan densitometry and is the average ± SEM of three inde-
pendent experiments. (C) The effect of CHL and EGCg on MT1-MMP functions was also monitored. U-87 cells were cultured 
in the presence of an exogenous source of proMMP-2 in the presence of 10 µg/ml concanavalin-A, a MT1-MMP-mediated 
inducer of proMMP-2 activation, and of EGCg or CHL. The extent of proMMP-2 activation was assessed by gelatin zymogra-
phy.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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G6PT regulates U-87 glioma cells migration Figure 3
G6PT regulates U-87 glioma cells migration. U-87 glioma cells were transfected with a cDNA plasmid encoding G6PT 
[36] as described in the methods section. (A) Total RNA was extracted from Mock or G6PT-transfected cells (Tx) and RT-
PCR was independently performed for G6PT and G6Pase-β gene expression. (B) Basal cell migration was assessed in Mock and 
G6PT-transfected U-87 cells as described in the Methods section in the presence or absence of 100 µM CHL. Six independent 
experiments were performed and the average of more than 10 microscopic fields for each experimental condition shown with 
SEM.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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express all three components of the G6Pase system with
G6Pase-β being predominant amongst these three (Fig.
1a). RT-PCR was also performed on RNA extracted from
U-87 glioma cells. In contrast to HEP-G2, only G6PT and
G6Pase-β transcripts were significantly expressed, with
very low to undetectable G6Pase-α present (Fig. 1a). This
Chlorogenic acid inhibits sphingosine-1-phosphate-induced U-87 glioma cells migration Figure 4
Chlorogenic acid inhibits sphingosine-1-phosphate-induced U-87 glioma cells migration. (A) Control (Mock) or 
G6PT-transfected U-87 glioma cells were seeded on gelatin-coated filters and cell migration was assessed in the presence or 
absence of 100 µM CHL, 1 µM S1P, or a combination of both. (B) Quantification was performed as described in the Methods 
section and is representative of 6 independent experiments. The average of more than 10 microscopic fields for each experi-
mental condition is shown with SEM.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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is in agreement with previous reports demonstrating the
lack of G6Pase-α expression in brain-derived cells [32].
We also monitored the levels of G6PT in a brain tumor
cell line derived from a pediatric medulloblastoma
(DAOY), as well as in the U-118 and U-138 glioma cell
lines. Interestingly, among the adult brain tumor-derived
cell lines, U-87 glioma cells expressed the highest level of
G6PT (Fig. 1b), while DAOY cells expressed very low to
undetectable G6PT transcripts. This suggests that G6PT
expression in brain tumor cells may be regulated during
development.
The G6PT inhibitor chlorogenic acid reduces proMMP-2 
secretion in U-87 glioma cells
We next assessed the potential functions that G6PT may
affect in the invasive phenotype of U-87 glioma cells.
Based on the assumption that CHL is able to efficiently
penetrate inside the cells [33], U-87 glioma cells were
treated with different concentrations of CHL and the
secretion of matrix metalloproteinase (MMP)-2 was mon-
itored by zymography. CHL significantly inhibited latent
proMMP-2 secretion (Fig. 2a) and another tea-derived
compound, epigallocatechin gallate (EGCg), was just as
efficient (Fig. 2a and 2b). CHL was found not to induce
any early/late apoptotic or necrotic processes in U-87 gli-
oma cells as assessed by Annexin-V/Propidium iodine
double staining and flow cytometry (not shown). Since
EGCg has also been reported to inhibit membrane type
(MT)1-MMP from activating the latent proMMP-2 in
glioblastoma cells [34], we further assessed the possible
effects of CHL on MT1-MMP-mediated proMMP-2 activa-
tion. Cells were incubated with an exogenous source of
proMMP-2 and were treated (or not) with concanavalin-A
in order to trigger proMMP-2 activation [35]. While EGCg
clearly inhibited MT1-MMP-mediated activation of
proMMP-2, CHL had no such inhibitory effect (Fig. 2c).
Chlorogenic acid inhibits G6PT-mediated U-87 glioma cell 
migration
The role of G6PT in U-87 glioma cell migration was next
assessed. Cells were transfected, or not (Mock), with G6PT
cDNA [36] and basal cell migration assay was performed
on gelatin-coated filters using modified Boyden chambers
as described in the Methods section. Transfection of G6PT
cDNA specifically increased G6PT transcript levels, while
levels of G6Pase-β remained unaffected (Fig. 3a). Interest-
ingly, the sole effect of G6PT overexpression was to
increase the basal migration of U-87 glioma cells (Fig. 3b,
white bars), while CHL inhibited both basal and G6PT-
induced cell migration (Fig. 3b, black bars). This suggests
that G6PT functions may, in part, regulate the invasive
phenotype of U-87 glioma cells.
Chlorogenic acid inhibits sphingosine-1-phosphate-
induced U-87 glioma cells migration
Sphingosine-1-phosphate (S1P) is a bioactive lipid which
is present at high levels in brain tissue [36] and which acts
as a potent mitogen for glioblastoma multiform cells [38].
Chlorogenic acid inhibits sphingosine-1-phosphate-induced ERK phosphorylation in U-87 glioma cells Figure 5
Chlorogenic acid inhibits sphingosine-1-phosphate-induced ERK phosphorylation in U-87 glioma cells. Serum-
starved U-87 glioma cells were pretreated with for 30 minutes with 100 µM CHL. One µM S1P was then added to the media 
and incubation performed for 15, 30, and 60 seconds. Cells were then rapidly harvested and lysates prepared as described in 
the Methods section. The extent of ERK phosphorylation was monitored by immunoblotting using antibodies against p-ERK 
and total ERK.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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Intracellular ATP-depleting agents inhibit proMMP-2 secretion and antagonize S1P-induced ERK phosphorylation in U-87 gli- oma cells Figure 6
Intracellular ATP-depleting agents inhibit proMMP-2 secretion and antagonize S1P-induced ERK phosphoryla-
tion in U-87 glioma cells. (A) Serum-starved U-87 glioma cells were treated for 18 hrs with individual concentrations of 2-
deoxyglucose or 5-thioglucose, two well established ATP-depleting agents [61]. Conditioned media were collected and the 
hydrolytic activity of proMMP-2 was assessed using gelatin-zymography as described in the Methods section. (B) The extent of 
proMMP-2 hydrolytic activity was quantified by scan densitometry in 5-TG- (black circles) and 2-DG- (white circles) treated 
cells, and is the average ± SEM of three independent experiments. (C) Serum-starved U-87 glioma cells were pretreated for 30 
minutes with 100 mM 2-deoxyglucose (2-DG) or 30 mM 5-thioglucose (5-TG). One µM S1P was then added to the media for 
15 seconds. Cells were then rapidly harvested and lysates prepared as described in the Methods section.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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More recently, S1P was shown also to potently enhance
the in vitro motility of glioblastoma cells [39]. We thus
assessed whether CHL could interfere with both basal and
S1P-induced cell migration in U-87 cells, and if it could
antagonize the G6PT-mediated regulation of cell migra-
tion. Control (Mock) or G6PT-transfected U-87 glioma
cells were harvested and seeded on top of gelatin-coated
filters as described in the Methods section. Cell migration
then occurred in the presence of either S1P, CHL, or a
combination of both. Representative images of stained
cells that had migrated through the filters are shown (Fig.
4a). We observed that S1P induced basal cell migration by
2.6-fold, and that CHL was able to inhibit both the basal
and S1P-induced cell migration (Fig. 4b, Mock). When
cells were transiently transfected with the G6PT cDNA,
basal cell migration increased by approximately 2-fold, in
accordance with Fig. 3b. Interestingly, the effect of S1P
was additive to that of the overexpression of G6PT, but
CHL efficiently antagonized migration that was induced
either by G6PT overexpression or by S1P in G6PT-trans-
fected cells (Fig. 4b, G6PT). These results suggest that
G6PT potentially regulates the intracellular signalling that
triggers basal and S1P-mediated cell migration, and that
functional inhibition of this signalling by CHL could
explain some of its chemopreventive effects at the molec-
ular level.
Chlorogenic acid inhibits sphingosine-1-phosphate-
induced ERK phosphorylation in U-87 glioma cells
S1P is thought to trigger intracellular signalling, in part,
through the MAPK pathway and the release of intracellu-
lar calcium pools [38,40]. We thus monitored the extent
of ERK phosphorylation that is triggered by S1P in U-87
glioma cells and whether CHL could interfere with that
process. S1P triggered a rapid phosphorylation of ERK
within the first 15 seconds of incubation (Fig. 5, left
panel). Interestingly, pre-incubation of the cells with 100
µM CHL for 30 minutes prevented that rapid phosphor-
ylation of ERK and even delayed it until a time of 60 sec-
onds (Fig. 5, right panel). This inhibitory effect of CHL on
S1P-induced ERK phosphorylation suggests that intracel-
lular inhibition of microsomal G6PT activity may antago-
nize crucial events taking place in the ER.
Intracellular ATP-depleting agents inhibit proMMP-2 
secretion and antagonize S1P-induced ERK 
phosphorylation in U-87 glioma cells
Besides its classical role in recognizing and translocating
G6P from the cytoplasm into the lumen of the ER, G6PT
has been attributed a possible role in regulating calcium
flux responses [41,42]. Such a role in regulating intracel-
lular calcium pools was elegantly demonstrated in neu-
trophils isolated from G6PT-deficient mice [43].
Interestingly, a functional link has been proposed
between G6P and calcium such that cytoplasmic G6P is
thought to enhance ATP-dependent sequestration of cal-
cium in the ER [30]. In light of this, we sought to investi-
gate the effects of the ATP-depleting agents and synthetic
analogs of glucose, the glucose 5-thioglucose (5-TG) and
the 2-deoxy-d-glucose (2-DG), on proMMP-2 secretion
and S1P-induced ERK phosphorylation. U-87 glioma cells
were serum-starved and treated with different concentra-
tions of 2-DG and 5-TG. Conditioned media was isolated
and the activity of secreted proMMP-2 was measured.
ProMMP-2 secretion was significantly decreased in both
2-DG- and 5-TG-treated cells (Fig. 6a). Half-maximal inhi-
bition constants (IC50) were calculated to be 2 mM and 19
mM, respectively, for 2-DG and 5-TG (Fig. 6b). S1P-
induced ERK phosphorylation was also monitored in 2-
DG- and 5-TG pre-treated cells, and both ATP-depleting
agents were able to inhibit S1P-induced ERK phosphor-
ylation (Fig. 6c). Although these data are indirect, alto-
gether they suggest that the inhibition of microsomal
G6PT functions (inhibition of ER G6P uptake or of ATP-
dependent calcium sequestration) leads to decreased
proMMP-2 secretion and a potential decrease in calcium-
mediated intracellular signalization.
Discussion
As part of our continuing search for potential anticancer
drug candidates, we pay great interest to natural products
for their potential anticancer activities. As such, among
the sources of anticancer polyphenols in tea constituents,
CHL has recently caught our attention as it has been
attributed chemopreventive properties [12-14]. Although
CHL is known as the most potent inhibitor of G6PT, no
study has yet demonstrated a role for G6PT in regulating
tumor progression and metastasis. Our study now pro-
vides a molecular rationale to the anticancer properties of
CHL in highly invasive brain tumor-derived U-87 gliob-
lastoma cells. Indeed, we highlight a new and underesti-
mated function for the microsomal G6PT as a potential
regulator of cancer cells invasive phenotype. Besides its
classical role in regulating the rate limiting step of G6P
transport, G6PT specific functional inhibition by CHL
even becomes more relevant when one considers G6PT's
potential role in regulating calcium-mediated signalling.
Such intracellular transduction events are known to regu-
late cancer cells proliferation, cell cycle division, ECM
degradation, and response to growth factors. We now sug-
gest that new cellular processes such as cell invasion, intra-
cellular signal transduction in response to growth factors,
and secretion of MMP may collectively be regulated in
part through G6PT-mediated ER functions.
Interestingly, we extensively investigated and demon-
strated that EGCg, another naturally occurring green tea-
derived polyphenol with anticancerous properties similar
to those we describe for CHL, can also efficiently target the
brain tumor invasive phenotype by inhibiting RhoA/Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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Rock-mediated intracellular cell signalling [44]. Moreo-
ver, in light of recent studies which have shown that EGCg
could also serve as an ionizing radiation (IR) enhancer
against cancer cell lines [45], we have further shown that
EGCg pretreatment of glioma cells prior to IR can reverse
the cytoprotective effect provided through the expression
of prosurvival proteins such as Survivin [46]. Functional
inhibition of G6PT by either CHL or by the ATP-depleting
agents 2-DG/5-TG could thus provide a molecular ration-
ale for the role that G6PT may play in the intracellular sig-
nalling regulating the high-grade radioresistant glioma
cells.
One important implication of our study is its potential
impact on targeting G6PT functions in radiotherapeutic
modalities. The failure of radiotherapy in cerebral gliomas
is primarily due to the diffusely infiltrating nature of the
tumor and the presence of a hypoxic, repair-proficient and
intrinsically radioresistant subpopulation of cells. Since
the chemopreventive properties of both the IR-cell sensi-
tizing agent EGCg [46] and of CHL molecules [this study]
are similarly and efficiently able to inhibit cell migration
and MMP-secretion of glioblastoma cells, it is tempting to
suggest that CHL may also be used in synergy with radio-
therapeutic modalities. Enhanced glucose usage in vitro as
well an in vivo, which correlates with the degree of malig-
nancy and with poor prognosis, has been demonstrated in
glioma tumors [52-54]. Moreover, in vitro studies in estab-
lished glioma cell lines showed that the presence of 2-DG
for a few hours after irradiation could increase radiation
damage significantly and that radiosensitization was
higher under conditions of reduced respiratory metabo-
lism [55]. Finally, 2-DG is known to inhibit glycolytic
energy ATP production [56] and has been tested in multi-
ple studies for possible application as an anticancer or
antiviral therapeutic [57-59]. Such observations provide
another molecular rationale for the means by which CHL,
2-DG and 5-TG that we report in the present study may
inhibit G6PT functions, and that we have shown to be sig-
nificantly expressed in U-87 glioblastoma cells.
Poorly differentiated and rapidly growing malignant
tumors are generally characterized by higher rates of glu-
cose usage and glycolysis as compared to corresponding
normal tissues [47,48]. As such, these fundamental differ-
ences in the glucose metabolism of transformed and nor-
mal cells form the basis for the noninvasive detection and
grading of tumors by positron emission tomography
(PET) using tracer nanomolar doses of [18F]-2-fluoro-
deoxyglucose ([18F]FDG), a nonmetabolizable analog of
glucose that enters the cell by the same membrane trans-
port mechanism as does glucose. Measurements of glu-
cose uptake into human tumors by FDG-PET suggest that
glucose uptake may directly correlate with the degree of
malignancy and treatment resistance/poor prognosis [49].
The precise molecular mechanisms underlying this corre-
lation remain to be elucidated. Interestingly, the use of
[18F]FDG was also employed in the monitoring of adeno-
virus-mediated GSD-1a correction [50], a disease charac-
terized by a defect in the glucose-6-phosphatase catalytic
subunit (G6Pase-α). Therefore, similar to the non-metab-
olizable glucose analogue 2-DG, one can expect pharma-
cological doses of FDG to block glycolysis and to cause
depletion of ATP. Interestingly, it has been shown that the
killing of neoplastic cells by cytostatic drugs is associated
with decreased ATP content and FDG uptake. This indi-
cates that FDG uptake is closely linked with ATP produc-
tion and that not only ATP but also FDG could be used to
study drug effects in vitro [51].
We show that inhibiting G6PT functions by CHL or by
ATP-depleting agents in brain-tumor-derived cells may
result in decreased invasiveness. Moreover, because cancer
cells frequently display high rates of aerobic glycolysis, in
comparison to their nontransformed counterparts, the
recently published hypoglycemic impact of CHL [60],
combined with the possible applications of 2-DG in anti-
cancer therapies, further supports the theory that inhibit-
ing G6PT functions in cancer cells could decrease tumor
progression. G6PT deficiencies lead to GSD type-Ib and
chronic neutropenia because of impaired glucose home-
ostasis [41,42], altered neutrophil chemotaxis and cal-
cium flux [43], and induction of cell apoptosis [22].
Concomitantly, CHL was recently found to inhibit human
hepatocellular carcinoma cell line proliferation [14] and
to induce apoptosis of chronic myelogenous leukemia
(CML) cell lines and primary cells from CML patients
[62]. Alternate cellular targets of CHL in glioma cells can
not be excluded as its most extensively studied effects were
attributed to its metal chelator, and that its anti-oxidative
properties highlighted a role for ERK in oxidative stress-
induced glioma cell death [63]. Although this remains to
be investigated, it thus becomes tempting to hypothesis
that the anti-oxidative properties of CHL may somehow
prevent or protect from oxidative stress-induced cell
death. Studies on the G6PT functions and contribution in
neurodegenerative diseases may shed some clues as to its
role and modulation by oxidative stress.
In summary, our study evidences that G6PT triggers can-
cer cell migration, and that CHL antagonized growth fac-
tors-induced calcium mobilization and ERK
phosphorylation. The sum of these experimental evi-
dences leads us to postulate a new role for G6PT in cancer
cell signalling, and suggests that efficient inhibition of the
G6PT functions will impact on the invasive and metastatic
phenotype of circulating cancer cells whether they derive
from solid tumors or from malignant clonal disorder of
hematopoietic stem cells such as CML.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
Page 10 of 12
(page number not for citation purposes)
Methods
Materials
Agarose, (-)-epigallocatechin 3-gallate (EGCg), sodium
dodecylsulfate (SDS), gelatin, and bovine serum albumin
(BSA) were purchased from Sigma (Oakville, ON). The
TRIzol reagent was from Life Technologies (Gaithersburg,
MD). FUGENE-6 transfection reagent was from Roche
Diagnostics Canada (Laval, QC).
Cell culture and cDNA transfection method
The U-87, U-118 and U-138 glioma cell lines, the DAOY
medulloblastoma cell line and the HEP-G2 hepatoma cell
line were purchased from American Type Culture Collec-
tion and cultured in their recommended media. Specifi-
cally, U-87 cells were maintained in Eagle's Minimum
essential medium (MEM) containing 10% (v/v) fetal
bovine serum (FBS) (HyClone Laboratories, Logan, UT),
2 mM glutamine, 100 units/ml penicillin and 100 µg/ml
streptomycin, and were cultured at 37°C under a humid-
ified atmosphere containing 5% CO2. The G6PT plasmid
was validated and generously provided by Dr Christopher
Newgard [35]. U-87 cells were transiently transfected with
the cDNA construct using the non-liposomal formulation
FUGENE-6 transfection reagent. Transfection efficiency
was confirmed by RT-PCR. All experiments involving
these cells were performed 36 hrs following transfection.
Mock transfections of U-87 cultures with pcDNA (3.1+)
expression vector alone were used as controls.
Total RNA isolation and reverse transcriptase-polymerase 
chain reaction (RT-PCR) analysis
Total RNA was extracted from cultured monolayers of U-
87 cells using the TRIzol reagent. One microgram of total
RNA was used for first strand cDNA synthesis followed by
specific gene product amplification with the One-Step RT-
PCR Kit (Invitrogen, Burlington, ON). Primers for
G6Pase-α (forward : 5'-TTCAGCCACATCCACAGCATC-
3', reverse : 5'-GGGGTTTCAAGGAGTCAAAGACG-3'), for
G6Pase-β (forward : 5'-ACTCTTCCTGACTTCTTGTGT-
GCC-3', reverse : 5'-TTGCCTTTGCTCTTTGGGGG-3') and
for G6PT (forward : 5'-CAGGGCTATGGCTATTATCG-
CAC-3', reverse : 5'-ATGGCTCAAACCACTTCCGCAG-3')
were all derived from human sequences. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) cDNA amplifica-
tion was used as an internal house-keeping gene control.
PCR conditions were optimized so that the gene products
were examined at the exponential phase of their amplifi-
cation and the products were resolved on 1.5% agarose
gels containing 1 µg/ml ethidium bromide.
Gelatin zymography
Gelatin zymography was used to assess the extent of
MMP-2 activity. Briefly, an aliquot (20 µl) of the culture
medium was subjected to SDS-PAGE in a gel containing
0.1 mg/ml gelatin. The gels were then incubated in 2.5%
Triton X-100 and rinsed in nanopure distilled H2O. Gels
were further incubated at 37°C for 20 hrs in 20 mM NaCl,
5 mM CaCl2, 0.02% Brij-35, 50 mM Tris-HCl buffer, pH
7.6, then stained with 0.1% Coomassie Brilliant blue R-
250 and destained in 10% acetic acid, 30% methanol in
H2O. Gelatinolytic activity was detected as unstained
bands on a blue background. The exogenous source of
proMMP-2, used to assess MT1-MMP-mediated activation
of proMMP-2 by concanavalin-A, was isolated from 48 hrs
serum starved-U87 glioma cells. This conditioned media
contains high levels of latent proMMP-2 as well as TIMP-
2 necessary to for the ternary complex with MT1-MMP
and to monitor any potential MT1-MMP-mediated activa-
tion of proMMP-2 activation.
Immunoblotting procedures
Proteins from control and treated cells were separated by
SDS-polyacrylamide gel electrophoresis (PAGE). After
electrophoresis, proteins were electrotransferred to poly-
vinylidene difluoride membranes which were then
blocked overnight at 4°C with 5% non-fat dry milk in
Tris-buffered saline (150 mM Tris, 20 mM Tris-HCl, pH
7.5) containing 0.3% Tween-20 (TBST). Membranes were
further washed in TBST and incubated with the primary
antibodies (1/1,000 dilution) in TBST containing 3%
bovine serum albumin, followed by a 1 hr incubation
with horseradish peroxidase-conjugated anti-rabbit IgG
(1/10,000 dilution) in TBST containing 5% non-fat dry
milk. Immunoreactive material was visualized by
enhanced chemiluminescence (Amersham Biosciences,
Baie d'Urfée, QC).
Cell migration assay
Cells were dislodged after brief trypsinization, washed
extensively and resuspended in DMEM at a concentration
of 106 cells/ml [35]. Cells (7 × 105) were then dispersed
onto 1 mg/ml gelatin/PBS-coated chemotaxis filters (Cos-
tar; 8-µm pore size) within Boyden chamber inserts.
Migration proceeded for 3 h at 37°C in 5% CO2. Cells that
had migrated to the lower surface of the filters were fixed
with 10% formalin phosphate, colored with 0.1% crystal
violet/20% MeOH and counted by microscopic examina-
tion. The average number of migrating cells per field was
assessed by counting at least four random fields per filter
using Northern Eclipse software. Data points indicate the
mean obtained from three separate chambers within one
representative experiment.
Statistical data analysis
Data are representative of three or more independent
experiments. Statistical significance was assessed using
nonparametric one-way ANOVA with GraphPad Prism
Version 4.0. Probability values of less than 0.05 were con-
sidered significant, and an asterisk (*) identifies such sig-
nificance in each figure.Cancer Cell International 2006, 6:7 http://www.cancerci.com/content/6/1/7
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